

Global Estrogen Receptor Agonist Market To Witness Incredible Growth

The global estrogen receptor agonist market is anticipated to grow at a CAGR of 15.76% over the forecast period (2022 - 2030).

PUNE, MAHARASHTRA, INDIA, March 30, 2022 /EINPresswire.com/ -- Selective Estrogen Receptor Agonist to Hold Largest Market Share in 2021

According to [Absolute Markets Insights](#) report, selective estrogen receptor agonist accounted for the highest market share in 2021 and is projected to maintain its dominance over the

forecast period (2022-2030) in the [estrogen receptor agonist market](#) as they act in organ/tissue specific fashion and avoid adverse, off-target effects. They are majorly used for the treatment of breast cancer, the prevention of osteoporosis, and the maintenance of beneficial serum lipid profiles in postmenopausal women. The increasing burden of chronic disease globally have resulted in the rising drug discovery and development activities by engaging computational tools and bioinformatics methodologies, thereby driving the development of selective estrogen receptor agonist drugs. For instance, Sanofi is developing amcenestrant, which has shown early signs of clinical efficacy in the phase 1/2 AMEERA-1 trial in postmenopausal women with heavily pretreated ER-positive, HER2-negative advanced or metastatic breast cancer. AMEERA-1 is evaluating amcenestrant as monotherapy and in combination with other anticancer therapies. Furthermore, the increasing funding for drug development is impelling the growth of selective estrogen receptor agonist segment. For instance, in July 2020, Olema Oncology received funding of USD 54 million to advance the breast cancer program OP-1250 into phase I/II clinical development and expand ongoing research and development activities in other cancers affecting women. Also, the increasing collaboration activities are anticipated to boost the segment growth. For instance, in July 2020, Zentalis Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, announced a clinical collaboration agreement with Eli Lilly and Company in which Zentalis will evaluate the combination of ZN-c5, the Company's



oral selective estrogen receptor degrader (SERD) product candidate, and Verzenio (abemaciclib), Lilly's CDK4 and 6 inhibitor, in patients with ER+/HER2- advanced breast cancer.

Get PDF sample report with related graphs & charts (Pre & post COVID-19 impact analysis):

https://www.absolutemarketsinsights.com/request_sample.php?id=1114

Key Findings – Global Estrogen Receptor Agonist Market

- In terms of revenue, the global estrogen receptor agonist market is anticipated to grow at a CAGR of 15.76% over the forecast period (2022 – 2030).
- By clinical indication, the cardiovascular health segment will be the fastest growing segment owing to the increasing incidence of CVDs across the globe. As per WHO, an estimated 17.9 million people died from CVDs in 2019. Also, the estrogen receptor agonist are proven efficient to treat CVDs, thereby impelling the segment growth.
- By route of administration, oral segment holds the largest market share in estrogen receptor agonist market owing to its cost efficiency and convenience. Also, they can be rapidly absorbed, thereby mostly preferred. For instance, raloxifene is rapidly absorbed after oral administration, and its absolute bioavailability is 2 %
- By distribution channel, the offline segment registered for the largest market revenue in 2021 and is anticipated to witness the fastest growth rate owing to the increasing number of pharmacies attached to hospitals. Also, the increasing demand for prescription drug is driving the segment growth. In 2021, the prescription drug revenue was estimated about USD 1,031 billion.
- By region, Asia-Pacific region is anticipated to witness the fastest growth over a forecast period owing to the increasing government initiatives and collaboration for the drug development.

Speak to our analyst in case of queries before buying this report:

https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=1114

Competitor Insights:

The key companies profiled in the global estrogen receptor agonist market are mentioned below:

- AstraZeneca
- Eli Lilly and Company
- ESTRIGENIX
- Karo Pharma AB
- Merck KGaA
- Oasmia Pharmaceutical AB
- Oncernal Therapeutics.
- Pfizer Inc.
- Tocris Bioscience
- Tokyo Chemical Industry Co., Ltd
- Other Market Participants

View our exclusive press releases on [Industry Global News24](#)

Global Estrogen Receptor Agonist Market

By Product Type

- Endogenous Estrogen Receptor Agonist
- Selective Estrogen Receptor Agonist
- Others

By Clinical Indication

- Breast Cancer
- Fertility
- PCOS
- Osteoporosis
- Neurodegenerative Disorders (Including Multiple sclerosis (MS))
- Inflammatory Diseases
- Cardiovascular Health
- Others

By Route of Administration

- Oral
- Parenteral

By Distribution Channel

- Online
- Offline

By Region

- North America (U.S., Canada, Mexico, Rest of North America)
- Europe (France, The UK, Spain, Germany, Italy, Nordic Countries, Benelux Union, Rest of Europe)
- Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- Latin America (Brazil, Argentina, Rest of Latin America)

Purchase the latest in-depth Estrogen Receptor Agonist Market Report @

<https://www.absolutemarketsinsights.com/checkout?id=1114>

Top Related Reports:

Global Compounding Chemotherapy Market –

<https://www.absolutemarketsinsights.com/reports/Global-Compounding-Chemotherapy-Market->

[2022-2030-1094](#)

Global Lumakras Market – <https://www.absolutemarketsinsights.com/reports/Global-Lumakras-Drug-Market-2021-2029-1089>

Global RNA-Targeted Small Molecules Market -

<https://www.absolutemarketsinsights.com/reports/RNA-Targeted-Small-Molecules-Market-2022-2029-1078>

About Us:

Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization.

From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.

Contact Us:

Contact Name: Shreyas Tanna

Company: Absolute Markets Insights

Email Id: sales@absolutemarketsinsights.com

Phone: IN +91-7400-24-24-24, US +1-510-420-1213

Website: www.absolutemarketsinsights.com

Shreyas Tanna

Absolute Markets Insights

+1 510-420-1213

sales@absolutemarketsinsights.com

This press release can be viewed online at: <https://www.einpresswire.com/article/566963574>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.